Actavis Appoints Two Former Members Of Allergan Board To Its Board - Quick Facts

(RTTNews) - Actavis plc (ACT) announced that two former members of the Allergan Board of Directors - Michael Gallagher, Lead Independent Director, and Peter McDonnell, - have been named to the Actavis Board of Directors.

David Pyott, Chairman and Chief Executive Officer of Allergan, has elected not to join the combined company's Board of Directors, but will continue to serve as Chairman of The Allergan Foundation, a U.S.-based, private charitable foundation committed to providing a lasting and positive impact in the communities in which Allergan, Inc. employees live and work.

In addition, the Actavis Board also includes Paul Bisaro Executive Chairman; Brenton Saunders, CEO and President; Catherine Klema, Nesli Basgoz,, James Bloem, Christopher Bodine, Christopher Coughlin, Patrick J. O'Sullivan, Ronald Taylor, and Fred Weiss.

On February 5, 2015, in preparation for the closing of the acquisition of Allergan, the Actavis Board of Directors voted to reduce the Actavis Board from 14 members to 12, and announced the voluntary resignation of Tamar Howson, John King, Jiri Michal and Andrew L. Turner, effective upon the close of the transaction.

Earlier today, Actavis announced that it has completed the acquisition of Allergan, Inc. (AGN) in a cash and equity transaction valued at approximately $70.5 billion.